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Background: The standard trimodal treatment concept in locally advanced and non-metastasized non-small-cell
superior sulcus tumors consists of a preoperative chemoradiation followed by surgical resection. High linear energy
transfer (LET) radiation as, for example, C12 heavy-ion beam therapy theoretically offers biological advantages
compared to high energy x-ray therapy as, for example, higher biological efficiency.
Methods/Design: In the present prospective, single-armed, open pilot study performed at the Heidelberg Ion-Beam
Therapy Center (HIT) in Heidelberg, the radiation treatment within the standard trimodal concept will be exchanged
against C12 heavy-ion beam treatment and apply 39GyE in 13 single fractions in combination with a chemotherapy
consisting of cisplatin and vinorelbine (local standard). The primary endpoint is feasibility and safety measured by
the incidence of NCI-CTCAE grade 3/4 toxicity and/or discontinuation due to any reason. Secondary endpoint is the
degree of regression in the histological specimen. The main inclusion criteria are histologically confirmed non-small-cell
superior sulcus tumor, nodal disease stage ≤ N2, Karnofsky performance score ≥70%, patient age between 18 and
75 years as well as written informed consent. The main exclusion criteria include medical contraindications against
elements of the trimodal treatment concept, PET confirmed nodal disease stage N3, stage IV disease, prior thoracic
irradiation and decompensated diseases of the lung, cardio-vascular system, metabolism, hematopoietic and coagulation
system and renal function. Furthermore, patients with implanted active medical devices without certification for ion-beam
therapy are not allowed to take part in the study. Trial registration number: DRKS00006323 (www.drks.de).
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Lung cancer is one of the most common cancers and
accounts for 14% of all cancers in men and 13% in
women [1]. The probability of lung cancer development
during lifetime is 7.6% in men and 6.3% in women. In
2014 there will be approximately 224.210 new cases of
lung and bronchial cancer in the United States. The
estimated 5-year survival rate is 17% [1]. Superior sulcus
tumors are a subtype of lung cancer, localized in the lung
apex and commonly of non-small-cell histology. Treatment
of choice is a preoperative chemoradiation followed by
surgical resection [2]. Rusch et al. reported on preoperative
radiotherapy applying 45Gy in combination with cisplatin* Correspondence: henrik.hauswald@med.uni-heidelberg.de
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unless otherwise stated.and etoposide chemotherapy. The results showed 36%
histological complete remissions in the surgical specimens.
Acute adverse events > CTC °2 were primarily bone
marrow suppressions. The trimodal treatment concept in
Heidelberg is platin-based as well and applies cisplatin in
combination with vinorelbine. The results of an en-block
resection of superior sulcus tumors in Heidelberg
were published by Pfannschmidt et al. in 2003 [3]. The
colleagues did not find an impact on survival stratified
by the radiotherapeutical concept, but a complete tumor
resection was prognostic. However, most patients in
their report did not receive chemotherapy in addition
to irradiation.
In the setting of phase I/II studies colleagues in Japan
evaluated heavy-ion therapy in stage I non-small-cell
lung cancer (NSCLC). A dose escalation trial evaluated
initially 47 patients treated in 18 fractions within 6 weeks
(>86.4GyE) and later 34 other patients treated in 9 fractionsral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 In- and exclusion criteria of the INKA study
Inclusion Criteria
Patients meeting all of the following criteria will be considered for
admission to the trial:
• histological confirmed superior sulcus tumor (NSCLC)
• maximal stage N2 in a FDG-PET-CT
• age between 18 and 75 years
• Karnofsky Performance Score ≥70
• Written informed consent (must be available before enrolment in the trial)
Exclusion Criteria
Patients presenting with any of the following criteria will not be
included in the trial:
• refusal of the patients to take part in the study
• medical contraindications against one of the parts in the trimodal
concept
• stage N3 disease in FDG-PET-CT
• stage IV disease
• previous radiotherapy to the thoracic region
• Participation in another clinical study or observation period of
competing trials, respectively
• no capacity to consent
• active medical devices, for which no approval for ion-therapy exists
(i.e. cardiac pacemaker, defibrillator, …)
• decompensated diseases of the lungs, cardio-pulmonal system,
metabolism, hematopoetic system, coagulation system or renal function
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reported in 3/81 patients, but all patients recovered
completely and furthermore, the pneumonitis was not
dose-limiting. The local control rates were 64% and
84%. The in-field recurrence rates of the initial series
were dose-dependent. Applying doses >86.4GyE in 18
fractions or 72GyE in 9 fractions resulted in local
control rates of 90% and 95%. Miyamoto et al. reported on
heavy-ion therapy in 50 patients suffering from stage I
NSCLC applying 72GyE in 9 fractions [5]. All patients
were followed-up for at least 5 years or until death. The
median follow-up time was 59.2 months and the local
control rate 94.7%. No pulmonary toxicity > CTC °3 was
reported. Comparable results were published by Hof et al.
in 2007 on stereotactic radiosurgery using photon beams
in stage I/II NSCLC [6]. Patients were treated with doses
of 19 to 30Gy prescribed to the isocenter. The 12-, 24-
and 36-months local control rates were 89.5%, 67.9%
and 67.9%, and showed an advantage for higher doses.
Furthermore, Grutters et al. reported in their meta-analysis
on stage I NSCLC comparing photons, protons and
heavy-ions a superiority of particles in comparison to
conformal radiotherapy, especially regarding the survival
probability; however, this survival advantage was compar-
able to stereotactic radiotherapy [7]. Furthermore, a trend
to fewer side effects in particle therapy was seen, even
though final conclusions could not be drawn.
Yamamoto et al. analyzed the surgical specimen in 4
patients having had surgical resection following heavy-ion
therapy with 18 x 3.3 GyE [8]. Endpoints were tumor
response and radiation induced changes within the
lung tissue. In 2 patients no surviving tumor cells
were found and in 2 other cases only scattered tumor
cells. Furthermore, they described pulmonary fibrosis
in the tissue surrounding the primary tumor, whereas
the intensity decreased with increasing distance from
the primary tumor site. Tissue having been irradiated
with less than 15GyE did not show signs of pulmonary
fibrosis. The authors concluded that their results
demonstrated the efficacy and safety of heavy-ion therapy
in NSCLC. Another team that evaluated radiographic
changes of the lung and pleura following heavy-ion
therapy were Nishimura and colleagues [9]. Their analysis
showed a correlation of the V20 and V40 with the severity
of the pulmonic changes. Furthermore, these changes
occurred 3 months after the treatment and the maximum
period was 6 months. In contrast, pleural changes
occurred median 4 months after the initiation of heavy-
ion therapy and correlated significantly with the PTV, V20
and V40. The effect on pulmonary function was evaluated
by Kadono et al. [10]. The authors reported a <8% decrease
in the forced expiratory volume in 1 second (FEV1)
6 and 12 months after heavy-ion therapy and rated
this decrease in the FEV1 as not-severe. The impact ofheavy-ion therapy on the migration and invasion of
NSCLC-cells (cell lines A549 and EBC-1) was analyzed by
Akino et al. [11]. The authors showed that heavy-ion ther-
apy suppresses the metastatic potential in these cell lines.
Methods and design
Study design
This is a monocentric, single-armed, open, prospective
pilot trial to generate basic data on hypofractionated
heavy-ion therapy in superior sulcus tumors. Our intention
is to test the safety and feasibility based on the incidence of
NCI-CTCAE °3/4 side effects and/or discontinuation due
to any reason. Objective of this pilot trial is the evaluation
of the safety and feasibility of a preoperative hypofrac-
tionated radiation concept using active beam lines and
C12-heavy-ions in the trimodal treatment approach of
superior sulcus tumors. The in- and exclusion criteria
are found in Table 1.
Endpoints
Primary endpoint is safety and feasibility based on the
incidence of NCI-CTCAE °3/4 side effects and/or discon-
tinuation due to any reason.
Secondary endpoint is the regression rate in the surgical
specimen according to Junker et al. [12]: grade I: no or
only little tumor regression; grade IIa: >10% vital tumor
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tumor regression. Furthermore, the metabolic tumor
regression (PERCIST 1.0) according to Wahl et al. [13]
will be evaluated as well as the morphologic tumor regres-
sion according to the RECIST criteria. Finally, quality of
life will be evaluated.Ethical aspects
Approval by the Ethics Committee of the Medical
Faculty of the University of Heidelberg (S-025/2013)
and the Federal Office of Radiation Protection (BfS)
(22463/2-2013-024) has been obtained. The trial is regis-
tered at the German Clinical Trials Register (www.drks.de;
DRKS00006323).Radiation therapy/treatment planning and dose
prescription
Target definition: gross tumor volume (GTV): the GTV is
defined as the visible superior sulcus tumor and the PET
positive lymph nodes. Clinical target volume (CTV): the
CTV is defined as the GTV with a safety margin. An
internal target volume (ITV) will be calculated on the
basis of an individual 4D-planning CT.
Organs at risk (OAR): following OARs will be contoured:
esophagus, lungs, brachial plexus, and spinal cord. The
tolerance doses described by Emami et al. [14] (1/3 of the
lungs ≤54% (α/β = 3Gy); spinal cord ≤ 92% (α/β = 2Gy)) or
the recommendations of the quantitative analysis of normal
tissue effects in the clinic (QUANTEC; lung V20 ≤ 30-35%,
mean lung dose 20-23Gy [15]) should be respected. The
brachial plexus and esophagus will be respected due to the
prescribed total dose.
Dose prescription: 95% of the ITV should receive 39GyE
in 13 fractions (5–6 fractions a week). BED2Gy: superior
sulcus tumor (α/β = 10Gy): 42Gy.
Chemotherapy: according to the local standard chemo-
therapy regimen: cycle 1: cisplatin 80mg/m2 body sur-
face & vinorelbine 25mg/m2 body surface; vinorelbine
25mg/m2 body surface on day 8; cycle 2 (concomitant to
irradiation): cisplatin 80mg/m2 body surface & vinorelbine
15mg/m2 body surface; vinorelbine 15mg/m2 body surface
on day 8.Figure 1 Flowchart of the INKA study.Course: suitability check, enlightenment of the patient,
informed consent, basic work-up including medical
history and physical examination, QLQ-C30 and LC13
questionnaires, pulmonary function tests (FEV1); chemo-
therapy cycle 1, planning 4D-CT, heavy-ion therapy
and concomitant chemotherapy cycle 2, restaging (FDG-
PET-CT, QLQ-C30, LC13, pulmonary function test)
followed by surgical resection in week 8, and follow-up
examination including the final study visit as well as
QLQ-C30 and LC13 in week 13-15. Flowcharts are found
in Figure 1 and Table 2.
Statistical considerations
Investigated populations
ITT population: the intention-to-treat (ITT) population
includes all patients enrolled into the study. This popula-
tion is defined according to the full analysis set (FAS) of
the ICH E9 [16]. It is the basis for the primary statistical
analysis.
PP population: the per-protocol (PP) population includes
the all patients of the ITT population who have under-
gone the complete treatment and whose documentation
is complete.
Safety population: the safety population includes all
patients who were enrolled into the trial and who
started the study treatment.
Study hypothesis and sample size
To use the data captured in this study in the most efficient
way, in addition to descriptive analyses of all documented
variables the results on tumor regression will be evaluated
using inferential statistics. Within the confirmatory analysis,
the null-hypothesis H0: p ≤ 0.20 will be tested, whereas p is
the rate of complete tumor regression. For sample size
calculation we assumed a rate p1 = 0.50. This choice
regarding the null- and alternative-hypothesis results from
a comparison with data from the literature (rate 0.36
reported by Rusch et al. 2007) and is justified by the
increased validity of ion beam therapy (chosen rate
p1 = 0.50 for the alternative-hypothesis) and the shorter
period of time between chemoradiation and surgical
resection in this study (approximately 2 weeks instead of
3–5 weeks, chosen rate p1 = 0.20 for the null-hypothesis).
Table 2 Overview of the INKA study
Examination/point in time Inclusion Prior to
chemotherapy







Medical history x x x x x x
FeV1 x x x x
Assessment of toxicity x x x x x x
Blood count x x x x x x x
FDG-PET-CT x
CT with i.v. contrast x x x x
Quality of life EORTC QLQ-C30, LC13 x x x x x
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test. A one-sided test at level α = 0.05 results in a power of
86% if 20 patients are included. This sample size is
expected to be recruited within a reasonable period of
time and allows a confirmatory statement on the efficacy of
the chosen treatment concept in addition to the informa-
tion gathered on safety and feasibility.
Discussion
Lung cancer is one of the most common types of cancer
with poor long-term survival rates. High complete
response rates were found in histopathologic examinations
following surgery with preoperative chemoradiation [2].
Even though a prior report by Pfannschmidt et al. did not
show an impact of the chosen radiation technique on
survival [3], recent studies demonstrated excellent re-
sults for local tumor control (>90%) after hypofractio-
nated heavy-ion beam therapy in early stage NSCLC
[4,5]. In addition, these excellent tumor control rates
were associated with low treatment related adverse
events [4,5,8]. For the dose calculations we assumed
an α/β of 10Gy for sulcus superior tumors resulting
in a BED2Gy of 42 Gy. To limit possible treatment-related
adverse events, the recommendations by Emami et al. and
QUANTEC were used [14,15].
Furthermore, high histopathological response rates
(50% complete remissions) might be achieved considering
the analysis by Yamamoto et al.; however, the num-
ber of analyzed specimens was small and higher
doses (18 x 3.3GyE up to 16 x 4.5GyE) but without
concurrent chemotherapy were applied [8]. Another
analysis of heavy-ion beam therapy on the tumor cell
migration and invasion suggested a suppression of
the metastatic potential in the analyzed cell lines [11].
Recently, colleagues from Chiba reported on respiratory-
gated carbon ion therapy in 34 patients treated for
lung metastases from colorectal cancer (CRC) [17].
The carbon ion treatment was well tolerated (only
Grade 1–2 adverse events) and achieved high local
tumor control rates, even though Takeda et al.
showed previously that lung metastases from CRC donot respond as well to stereotactic body radiation
therapy [18]. Considering those reports we assume
that the results of a preoperative heavy-ion beam
therapy in combination with chemotherapy followed
by surgical tumor resection might improve the outcome
following high-linear energy transfer heavy-ion beam
therapy in comparison to standard photon beam ther-
apy for example due to biological effects allowing us
to optimize the treatment results in the future while
keeping treatment related adverse events minimal.
Therefore, this prospective single-arm pilot trial is
primarily aimed to evaluate the safety and feasibility
of heavy-ion beam therapy for sulcus superior tumors
in the trimodal setting. Secondary endpoint is the degree
of regression in the histopathological specimen. In case of
promising results, the information generated in the
present trial will be used to plan a confirmatory study.
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